enGene Holdings Net Loss Widens 21% to $29.8M in Q1 FY2026

enGene Holdings Inc., a clinical-stage biotechnology company developing gene therapies, reported a net loss of $29.8 million for the three months ending January 31, 2026, compared with a net loss of $24.6 million in the same period a year earlier. The company reported no revenue for the quarter. Read more earnings reports.

Operating expenses rose to $31.2 million from $26.6 million in the prior-year quarter, a 17% increase. The operating loss for Q1 FY2026 reached $31.2 million, up from $26.6 million a year ago.

Research Spending Drives Cost Increase

Research and development expenses totaled $22.3 million in the quarter, up 11% from $20.0 million in Q1 FY2025. General and administrative expenses climbed to $3.8 million from $3.0 million, a 25% jump.

Cash and cash equivalents stood at $36.6 million as of January 31, 2026, down from $50.2 million at the end of October 2025. The company used $28.9 million in operating activities during the quarter, compared with $25.7 million in the year-ago period.

Capital Raise Boosts Balance Sheet

Total assets increased to $337.1 million as of January 31, 2026, up from $221.5 million three months earlier. The quarter saw cash from financing activities of $141.7 million, while cash from investing activities consumed $126.3 million.

Stockholders' equity rose to $281.5 million from $167.7 million as of October 31, 2025. The company's accumulated deficit widened to $401.8 million from $372.0 million over the same period.

Common shares outstanding increased to 67.0 million at quarter-end from 52.0 million in October 2025. Total liabilities stood at $55.6 million, including $24.9 million in long-term debt.